EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Equidacent August 6, 2020 Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... July 12, 2024 Cancer Research UK honours Her Majesty The Queen, the charity’s Patron September 8, 2022 Predicting future breast cancer with precision March 22, 2021 Load more HOT NEWS HBV Infection Associated with Increased Risk of Primary Extrahepatic Malignancies Fertility Preservation Safe for Young Women with Breast Cancer FDA Approves New and Updated Indications for Temozolomide Under Project Renewal Darolutamide Extends Survival for Some People with Metastatic Prostate Cancer
